IL156282A0 - Eg-vegf/prokineticin 2-receptor antagonists - Google Patents

Eg-vegf/prokineticin 2-receptor antagonists

Info

Publication number
IL156282A0
IL156282A0 IL15628203A IL15628203A IL156282A0 IL 156282 A0 IL156282 A0 IL 156282A0 IL 15628203 A IL15628203 A IL 15628203A IL 15628203 A IL15628203 A IL 15628203A IL 156282 A0 IL156282 A0 IL 156282A0
Authority
IL
Israel
Prior art keywords
vegf
nucleic acid
polypeptide
growth factor
vascular endothelial
Prior art date
Application number
IL15628203A
Other versions
IL156282A (en
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of IL156282A0 publication Critical patent/IL156282A0/en
Publication of IL156282A publication Critical patent/IL156282A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A composition that contains, as active agent (A), an endocrine gland vascular endothelial growth factor (EG-VEGF) nucleic acid, polypeptide or antisense nucleic acid, antibody against EG-VEGF or its receptor (EG-VEGF-R), or EG-VEGF-R antisense nucleic acid, is useful for the treatment or prevention of endometrial diseases : Independent claims are also included for the following: (1) method for detecting uterine receptivity by determining the amount of EG-VEGF polypeptide and/or nucleic acid, using the new composition; or (2) test system for identifying antagonists (B) of EG-VEGF-R. ACTIVITY : Cytostatic; Gynecological. No details of tests for these activities are given. MECHANISM OF ACTION : Inhibiting activity or expression of endocrine gland vascular endothelial growth factor (EG-VEGF) , which is overexpressed in patients with endometriosis; gene therapy.
IL156282A 2002-06-26 2003-05-03 Eg-vegf/prokineticin 2-receptor antagonists IL156282A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2002129379 DE10229379A1 (en) 2002-06-26 2002-06-26 Treatment and prevention of endometrial disease, e.g. endometriosis or carcinoma, by inhibiting endocrine gland vascular endothelial growth factor, also diagnosis

Publications (2)

Publication Number Publication Date
IL156282A0 true IL156282A0 (en) 2004-01-04
IL156282A IL156282A (en) 2010-05-31

Family

ID=29796036

Family Applications (1)

Application Number Title Priority Date Filing Date
IL156282A IL156282A (en) 2002-06-26 2003-05-03 Eg-vegf/prokineticin 2-receptor antagonists

Country Status (7)

Country Link
EP (1) EP1386615B1 (en)
JP (1) JP4663968B2 (en)
AT (1) ATE422896T1 (en)
AU (1) AU2003204933B2 (en)
DE (2) DE10229379A1 (en)
ES (1) ES2321822T3 (en)
IL (1) IL156282A (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1589033A4 (en) * 2003-01-22 2006-04-12 Takeda Pharmaceutical Antibody and use thereof
GB0320238D0 (en) 2003-08-29 2003-10-01 Medical Res Council Treatment of disease
KR20150084007A (en) 2012-11-13 2015-07-21 리제너론 파아마슈티컬스, 인크. Anti-prokineticin receptor (prokr) antibodies and uses thereof
WO2018108862A1 (en) * 2016-12-12 2018-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of prokineticin receptor 2 for use as a medicament for treating an eg-vegf-related cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410533D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
WO2000075327A1 (en) * 1999-06-02 2000-12-14 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
DE19841985A1 (en) * 1998-09-03 2000-03-09 Schering Ag New heterocyclic alkanesulfonic and alkane carboxylic acid derivatives are VEGF receptor blockers useful in treatment of e.g. psoriasis, rheumatoid arthritis, stroke, tumors and endometriosis
AU2002230778A1 (en) * 2000-11-03 2002-05-15 The Regents Of The University Of California Prokineticin polypeptides, related compositions and methods
US6780787B2 (en) * 2002-03-21 2004-08-24 Lam Research Corporation Low contamination components for semiconductor processing apparatus and methods for making components

Also Published As

Publication number Publication date
DE50311184D1 (en) 2009-04-02
AU2003204933A1 (en) 2004-01-15
EP1386615A1 (en) 2004-02-04
EP1386615B1 (en) 2009-02-18
JP4663968B2 (en) 2011-04-06
ATE422896T1 (en) 2009-03-15
JP2004043468A (en) 2004-02-12
IL156282A (en) 2010-05-31
DE10229379A1 (en) 2004-01-29
ES2321822T3 (en) 2009-06-12
AU2003204933B2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
Granchi et al. Expression and regulation of endothelin-1 and its receptors in human penile smooth muscle cells
Eng et al. Renal proliferative and phenotypic changes in rats with two-kidney, one-clip Goldblatt hypertension
DE60315296D1 (en) Cell-selective delivery system
HUP0200186A2 (en) Use of casb616 polypeptides and polynucleotides for cancer treatment
WO2004076639B1 (en) Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
IS7770A (en) Neutralizing antibodies against GDF-8 and their use
CA2501719C (en) Remedy or preventive for kidney disease and method of diagnosing kidney disease
AU7934900A (en) Method of screening for inhibitors of asp2
NO971341D0 (en) Promoter for receptor tyrosine kinase TIE
WO2003062792A3 (en) Methods for determining drug responsiveness
WO2000006086A3 (en) Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
Maeda et al. Expression of CGRP, vasculogenesis and osteogenesis associated mRNAs in the developing mouse mandible and tibia
DE69720241T2 (en) LIGAND (TIE LIGAND-4) FROM THE TIE-2 RECEPTOR AND THEIR USE
ATE466020T1 (en) NEW ISOFORM OF VASCULAR DOTHELIAL CELL GROWTH INHIBITOR (VEGI)
IL156282A0 (en) Eg-vegf/prokineticin 2-receptor antagonists
DE69534419D1 (en) INTRA-CELLULAR ISOFORM OF INTERLEUKIN-1 RECEPTOR ANTAGONIST
Stevenson et al. Tissue inhibitor of metalloproteinase 1 regulates matrix metalloproteinase activity during newt limb regeneration
ATE335496T1 (en) ANGIOTENSIN II AND ANALOGUES FOR LIMITING SCARS AND ADHESION FORMATION
Wagner et al. TNF-α modulation via Etanercept restores bone regeneration of atrophic non-unions
CA2367360A1 (en) Insulin-like growth factor binding protein-4 protease
TW200501988A (en) Nucleic acids, polypeptides, and methods for modulating apoptosis
JP2003530841A (en) Therapeutic compounds and methods
DK1095143T3 (en) Inhibitor for the diagnosis and treatment of patients with haemophilia A
Kennedy et al. Basic FGF regulates interstitial collagenase gene expression in human smooth muscle cells
DE60333747D1 (en) DNA ENZYME FOR INHIBITING PLASMINOGENACTIVATOR INHIBITOR-1

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees